The US Food and Drug Administration’s fifth Rx-to-OTC switch approval in 2020, a lice treatment, doesn’t mark the substantial expansion in public health benefits that the agency and industry stakeholders envision for making drugs available nonprescription.
The FDA on 27 October said it approved a supplemental new drug application from Arbor Pharmaceuticals LLC for a full...







